Skip to main content
Fig. 5 | Journal of Translational Medicine

Fig. 5

From: SOX9 drives the epithelial–mesenchymal transition in non-small-cell lung cancer through the Wnt/β-catenin pathway

Fig. 5

EMT induced by SOX9 could be reversed by the β-catenin inhibitor XAV-939. a Western blot of the β-catenin, E-cadherin and N-cadherin proteins after treatment with the β-catenin inhibitor XAV-939 (100 μM) for 48 h in the indicated cells. β-Tubulin was used as a loading control. b Immunofluorescence of subcellular β-catenin and E-cadherin localization after treatment with the β-catenin inhibitor XAV-939 (100 μM) for 48 h in the indicated cells. c Wound healing assay to detect the migration ability after treatment with the β-catenin inhibitor XAV-939 (100 μM) for 48 h in the indicated cells. d Quantify the wound healing assay from c, ***p < 0.0001. e The Trans-well assay with or without Matrigel was performed in SOX9-overexpression cell lines after treatment with the β-catenin inhibitor XAV-939 (100 μM) for 48 h. The number of cells that passed through the bottom chamber are quantified and shown in the right panel, ***p < 0.0001

Back to article page